Repository logo
 
Publication

The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes

dc.contributor.authorSantos, Marlene
dc.contributor.authorLima, Luis
dc.contributor.authorCARVALHO, SERAFIM
dc.contributor.authorMota-Pereira, Jorge
dc.contributor.authorPimentel, Paulo
dc.contributor.authorMaia, Dulce
dc.contributor.authorCorreia, Diana
dc.contributor.authorBarroso, M. Fátima
dc.contributor.authorGomes, Sofia
dc.contributor.authorCruz, Agostinho
dc.contributor.authorMedeiros, Rui
dc.date.accessioned2024-07-23T10:43:21Z
dc.date.available2024-07-23T10:43:21Z
dc.date.issued2023-04
dc.description.abstractThis study aimed to investigate the influence of genetic variants in neuroplasticity-related genes on antidepressant treatment phenotypes. The BDNF-TrkB signaling pathway, as well as the downstream kinases Akt and ERK and the mTOR pathway, have been implicated in depression and neuroplasticity. However, clinicians still struggle with the unpredictability of antidepressant responses in depressed patients. We genotyped 26 polymorphisms in BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 in 80 patients with major depressive disorder treated according to the Texas Medical Algorithm for 27 months at Hospital Magalhães Lemos, Porto, Portugal. Our results showed that BDNF rs6265, PTEN rs12569998, and SYN1 rs1142636 SNP were associated with treatment-resistant depression (TRD). Additionally, MAPK1 rs6928 and GSK3B rs6438552 gene polymorphisms were associated with relapse. Moreover, we found a link between the rs6928 MAPK1 polymorphism and time to relapse. These findings suggest that the BDNF, PTEN, and SYN1 genes may play a role in the development of TRD, while MAPK1 and GSK3B may be associated with relapse. GO analysis revealed enrichment in synaptic and trans-synaptic transmission pathways and glutamate receptor activity with TRD-associated genes. Genetic variants in these genes could potentially be incorporated into predictive models of antidepressant response.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSantos M, Lima L, Carvalho S, et al. The Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypes. Int J Mol Sci. 2023;24(7):6758. doi:10.3390/ijms24076758pt_PT
dc.identifier.doi10.3390/ijms24076758pt_PT
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10400.16/3019
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://doi.org/10.3390/ijms24076758pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectADpt_PT
dc.subjectBDNFpt_PT
dc.subjectGSK3Bpt_PT
dc.subjectMAPKpt_PT
dc.subjectPTENpt_PT
dc.subjectSYN1pt_PT
dc.subjectgenetic polymorphismspt_PT
dc.subjectneuroplasticitypt_PT
dc.subjecttreatment-resistant depressionpt_PT
dc.titleThe Impact of BDNF, NTRK2, NGFR, CREB1, GSK3B, AKT, MAPK1, MTOR, PTEN, ARC, and SYN1 Genetic Polymorphisms in Antidepressant Treatment Response Phenotypespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceSwitzerlandpt_PT
oaire.citation.issue7pt_PT
oaire.citation.startPage6758pt_PT
oaire.citation.titleInternational Journal of Molecular Sciencespt_PT
oaire.citation.volume24pt_PT
person.familyNameDIAS DE CARVALHO
person.givenNameSERAFIM ARMINDO
person.identifier.ciencia-id0D1F-E365-C661
person.identifier.orcid0000-0002-6181-0096
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication7279bff2-1eb8-4a4f-a0d0-174a484cddfc
relation.isAuthorOfPublication.latestForDiscovery7279bff2-1eb8-4a4f-a0d0-174a484cddfc

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Santos-2023-The-impact-of-bdnf-ntrk-ngfr-creb-g.pdf
Size:
782.01 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description: